Literature DB >> 8529318

Small bowel permeability--a variable effect of NSAIDS.

V M Choi1, J E Coates, J Chooi, A B Thomson, A S Russell.   

Abstract

The baseline permeability of small bowel in 57 healthy volunteers was assessed by measuring the mannitol and chromium-EDTA recovery in a 5-hour urine collection after ingestion of a drink containing a mixture of 1 g of mannitol and 3.7 MBq of 51Cr-EDTA. Subjects were treated with medication for 1 week followed by permeability studies as described above. The regimens used were diclofenac sodium (Voltaren) 50 mg po tid (21 subjects), Voltaren SR 75 mg bid for 1 week (34 subjects), indomethacin 50 mg tid (10 subjects), and tenoxicam (Mobiflex) 20 mg daily (13 subjects). There was no significant difference between the mannitol recoveries at baseline or after any of the drugs. The permeability was clearly increased by indomethacin and by Voltaren SR. Conventional-release Voltaren increased permeability, but the results were not significantly above baseline. Mobiflex had no influence on the measured permeability. Our results suggest that the SR preparation of diclofenac has a more pronounced effect than regular diclofenac sodium; thus different NSAIDs and different preparations of the same NSAID may have different effects on small bowel permeability.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8529318

Source DB:  PubMed          Journal:  Clin Invest Med        ISSN: 0147-958X            Impact factor:   0.825


  7 in total

Review 1.  Choosing the right nonsteroidal anti-inflammatory drug for the right patient: a pharmacokinetic approach.

Authors:  N M Davies; N M Skjodt
Journal:  Clin Pharmacokinet       Date:  2000-05       Impact factor: 6.447

2.  Human intestinal permeability of piroxicam, propranolol, phenylalanine, and PEG 400 determined by jejunal perfusion.

Authors:  N Takamatsu; L S Welage; N M Idkaidek; D Y Liu; P I Lee; Y Hayashi; J K Rhie; H Lennernäs; J L Barnett; V P Shah; L Lesko; G L Amidon
Journal:  Pharm Res       Date:  1997-09       Impact factor: 4.200

Review 3.  Clinical pharmacokinetics of diclofenac. Therapeutic insights and pitfalls.

Authors:  N M Davies; K E Anderson
Journal:  Clin Pharmacokinet       Date:  1997-09       Impact factor: 6.447

4.  Influence of dosage form on the gastroenteropathy of flurbiprofen in the rat: evidence of shift in the toxicity site.

Authors:  N M Davies; F Jamali
Journal:  Pharm Res       Date:  1997-11       Impact factor: 4.200

5.  Indomethacin enhances bile salt detergent activity: relevance for NSAIDs-induced gastrointestinal mucosal injury.

Authors:  M Petruzzelli; A Moschetta; W Renooij; M B M de Smet; G Palasciano; P Portincasa; K J van Erpecum
Journal:  Dig Dis Sci       Date:  2006-04       Impact factor: 3.199

6.  Dependency of gastrointestinal toxicity on release rate of tiaprofenic acid: a novel pharmacokinetic-pharmacodynamic model.

Authors:  M Vakily; F Khorasheh; F Jamali
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

7.  Effect of drug release rate on therapeutic outcomes: formulation dependence of gastrointestinal toxicity of diclofenac in the rat.

Authors:  Tahereh Khazaeinia; Fakhreddin Jamali
Journal:  Inflammopharmacology       Date:  2004       Impact factor: 4.473

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.